Antifibrotic effects of luteolin on hepatic stellate cells and liver fibrosis by targeting AKT/mTOR/p70S6K and TGFβ/Smad signalling pathways

Liver International

Volumn 35, Issue 4, 2015, Pages 1222-1233

  Li, Jie ^a,b   Li, Xingxia ^a   Xu, Weiheng ^c   Wang, Shaozhan ^c   Hu, Zhenlin ^c   Zhang, Qing ^d   Deng, Xing ^d   Wang, Jing ^a   Zhang, Junping ^c   Guo, Cheng ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Activation; AKT; Hepatic fibrosis; Hepatic stellate cells; Luteolin; Smad

Indexed keywords

4 [4 (1,3 BENZODIOXOL 5 YL) 5 (2 PYRIDINYL) 1H IMIDAZOL 2 YL]BENZAMIDE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CASPASE 3; COLLAGEN; CYCLIN DEPENDENT KINASE 2; CYCLIN E; LUTEOLIN; MAMMALIAN TARGET OF RAPAMYCIN; PLATELET DERIVED GROWTH FACTOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN P53; S6 KINASE; SMAD PROTEIN; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; MADH2 PROTEIN, RAT; MTOR PROTEIN, RAT; RIBOSOMAL PROTEIN S6 KINASE, 70KD, POLYPEPTIDE 1; TARGET OF RAPAMYCIN KINASE; TGFB1 PROTEIN, RAT; TRANSFORMING GROWTH FACTOR BETA1;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT LIGATION; CARBON TETRACHLORIDE-INDUCED LIVER FIBROSIS; CELL INVASION ASSAY; CELL MIGRATION; CELL PROLIFERATION; CELL PROLIFERATION ASSAY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DIMETHYLNITROSAMINE-INDUCED LIVER FIBROSIS; DRUG ACTIVITY; DRUG EFFICACY; DRUG TARGETING; ENZYME ACTIVITY; EXPERIMENTAL LIVER FIBROSIS; G1 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; IN VIVO STUDY; LIVER PROTECTION; MALE; MONOTHERAPY; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; STELLATE CELL; WESTERN BLOTTING; ANIMAL; CELL LINE; CELL MOTION; CELL PROTECTION; DOSE RESPONSE; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; ENZYME ACTIVATION; ENZYMOLOGY; LIVER CIRRHOSIS, EXPERIMENTAL; METABOLISM; PATHOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ANIMALS; APOPTOSIS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; COLLAGEN; CYTOPROTECTION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-INDUCED LIVER INJURY; ENZYME ACTIVATION; G1 PHASE CELL CYCLE CHECKPOINTS; HEPATIC STELLATE CELLS; LIVER CIRRHOSIS, EXPERIMENTAL; LUTEOLIN; MALE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS, SPRAGUE-DAWLEY; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIGNAL TRANSDUCTION; SMAD2 PROTEIN; TOR SERINE-THREONINE KINASES; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84924553458     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12638     Document Type: Article

References (37)

1. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-69.
2. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001; 21: 437-51.
3. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 2011; 25: 195-206.
4. Friedman SL. Transcriptional regulation of stellate cell activation. J Gastroenterol Hepatol 2006; 21(Suppl 3): S79-83.
5. Reif S, Lang A, Lindquist JN, et al. The role of focal adhesion kinase-phosphatidylinositol 3-kinase-akt signaling in hepatic stellate cell proliferation and type I collagen expression. J Biol Chem 2003; 278: 8083-90.
6. Marra F, Arrighi MC, Fazi M, et al. Extracellular signal-regulated kinase activation differentially regulates platelet-derived growth factor's actions in hepatic stellate cells, and is induced by in vivo liver injury in the rat. Hepatology 1999; 30: 951-8.
7. Rippe RA, Brenner DA. From quiescence to activation: gene regulation in hepatic stellate cells. Gastroenterology 2004; 127: 1260-2.
8. Dooley S, Streckert M, Delvoux B, Gressner AM. Expression of Smads during in vitro transdifferentiation of hepatic stellate cells to myofibroblasts. Biochem Biophys Res Commun 2001; 283: 554-62.
9. Liu Y, Wang Z, Kwong SQ, et al. Inhibition of PDGF, TGF-beta, and Abl signaling and reduction of liver fibrosis by the small molecule Bcr-Abl tyrosine kinase antagonist Nilotinib. J Hepatol 2011; 55: 612-25.
10. Wang Y, Gao J, Zhang D, et al. New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol 2010; 53: 132-44.
11. Liu Y, Wen XM, Lui EL, et al. Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258. Lab Invest 2009; 89: 1152-60.
12. Liu X, Hu H, Yin JQ. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 2006; 26: 8-22.
13. Lopez-Lazaro M. Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem 2009; 9: 31-59.
14. Harborne JB, Williams CA. Advances in flavonoid research since 1992. Phytochemistry 2000; 55: 481-504.
15. Seelinger G, Merfort I, Schempp CM. Anti-oxidant, anti-inflammatory and anti-allergic activities of luteolin. Planta Med 2008; 74: 1667-77.
16. Ziyan L, Yongmei Z, Nan Z, Ning T, Baolin L. Evaluation of the anti-inflammatory activity of luteolin in experimental animal models. Planta Med 2007; 73: 221-6.
17. Ueda H, Yamazaki C, Yamazaki M. Luteolin as an anti-inflammatory and anti-allergic constituent of Perilla frutescens. Biol Pharm Bull 2002; 25: 1197-202.
18. Perez-Garcia F, Adzet T, Canigueral S. Activity of artichoke leaf extract on reactive oxygen species in human leukocytes. Free Radic Res 2000; 33: 661-5.
19. Domitrovic R, Jakovac H, Tomac J, Sain I. Liver fibrosis in mice induced by carbon tetrachloride and its reversion by luteolin. Toxicol Appl Pharmacol 2009; 241: 311-21.
20. Yue HY, Yin C, Hou JL, et al. Hepatocyte nuclear factor 4alpha attenuates hepatic fibrosis in rats. Gut 2010; 59: 236-46.
21. Zhong W, Shen WF, Ning BF, et al. Inhibition of extracellular signal-regulated kinase 1 by adenovirus mediated small interfering RNA attenuates hepatic fibrosis in rats. Hepatology 2009; 50: 1524-36.
22. Kang LP, Qi LH, Zhang JP, et al. Effect of genistein and quercetin on proliferation, collagen synthesis, and type I procollagen mRNA levels of rat hepatic stellate cells. Acta Pharmacol Sin 2001; 22: 793-6.
23. Wang Y, Jiang XY, Liu L, Jiang HQ. Phosphatidylinositol 3-kinase/Akt pathway regulates hepatic stellate cell apoptosis. World J Gastroenterol 2008; 14: 5186-91.
24. Gandhi CR, Sproat LA, Subbotin VM. Increased hepatic endothelin-1 levels and endothelin receptor density in cirrhotic rats. Life Sci 1996; 58: 55-62.
25. Garcia L, Hernandez I, Sandoval A, et al. Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol 2002; 37: 797-805.
26. Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest 1998; 102: 538-49.
27. Abriss B, Hollweg G, Gressner AM, Weiskirchen R. Adenoviral-mediated transfer of p53 or retinoblastoma protein blocks cell proliferation and induces apoptosis in culture-activated hepatic stellate cells. J Hepatol 2003; 38: 169-78.
28. Novo E, Marra F, Zamara E, et al. Overexpression of Bcl-2 by activated human hepatic stellate cells: resistance to apoptosis as a mechanism of progressive hepatic fibrogenesis in humans. Gut 2006; 55: 1174-82.
29. Marra F, Romanelli RG, Giannini C, et al. Monocyte chemotactic protein-1 as a chemoattractant for human hepatic stellate cells. Hepatology 1999; 29: 140-8.
30. Kinnman N, Hultcrantz R, Barbu V, et al. PDGF-mediated chemoattraction of hepatic stellate cells by bile duct segments in cholestatic liver injury. Lab Invest 2000; 80: 697-707.
31. Gumbiner B, Stevenson B, Grimaldi A. The role of the cell adhesion molecule uvomorulin in the formation and maintenance of the epithelial junctional complex. J Cell Biol 1988; 107: 1575-87.
32. Svegliati-Baroni G, de Minicis S, Marzioni M. Hepatic fibrogenesis in response to chronic liver injury: novel insights on the role of cell-to-cell interaction and transition. Liver Int 2008; 28: 1052-64.
33. Zhou Q, Yan B, Hu X, et al. Luteolin inhibits invasion of prostate cancer PC3 cells through E-cadherin. Mol Cancer Ther 2009; 8: 1684-91.
34. Seelinger G, Merfort I, Wolfle U, Schempp CM. Anti-carcinogenic effects of the flavonoid luteolin. Molecules 2008; 13: 2628-51.
35. Middleton E, Jr, Kandaswami C, Theoharides TC. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol Rev 2000; 52: 673-751.
36. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 2009; 50: 1294-306.
37. Domitrovic R, Jakovac H, Grebic D, Milin C, Radosevic-Stasic B. Dose- and time-dependent effects of luteolin on liver metallothioneins and metals in carbon tetrachloride-induced hepatotoxicity in mice. Biol Trace Elem Res 2008; 126: 176-85.